News Release

Research Article Highlights Advantageous Use Of AlbuVoid™ in Clinical Proteomics 

MONMOUTH JUNCTION, NJ , March 1, 2019 -- Biotech Support Group reports on a new research report which highlights the simplicity and efficiency of their Albumin depletion sample preparation technology as an enrichment step for clinical research of human serum using LC-MS proteomic analysis. The citation is: 

Vialaret, Jerome & Kadi, Sarah & Tiers, Laurent & O Flynn, Robin & Lehmann, Sylvain & Hirtz, Christophe. (2018). Albumin depletion of human serum to improve quantitative clinical proteomics. Current Topics in Peptide & Protein Research 19. 53-62.

http://www.researchtrends.net/tia/abstract.asp?in=0&vn=19&tid=26&aid=6192&pub=2018&type=3

Proteins are essential for biomarker and disease discovery though the most abundant proteins often provide very limited clinically relevant data, as can be the case for albumin or immunoglobulins. In this work, the investigators focused on depleting albumin from human serum samples using an albumin depletion and low abundance protein enrichment kit – AlbuVoid™, which enabled the detection of several low-abundance proteins. By employing an optimized protocol, enriched proteins known as biomarkers for various diseases were identified. The article states “Protein capture was performed using AlbuVoid™ Kit on serum samples… For the LCMS analysis, elution was made directly on the beads with denaturant solution (30 μL of 8 M urea / 20 mM DTT / 100 mM Tris pH 8.5) before tryptic digestion. In comparison, methods using antibodies needed at least one-half day more. The albumin depletion method allowed to save precious time. ”. The authors concluded that the AlbuVoid™ depletion method proved to be faster and more cost-effective than antibody based methods, and could be helpful for biomarker enrichment and detection in medical research.

“Throughout our product and methods development efforts, we have been especially focused on overcoming the challenges of clinical proteomics. So I am are very pleased to see that AlbuVoid™ was advantageously used for this purpose. Because we use a porous silica bead surface chemistry, the strong denaturing conditions studied here as the bead eluent. can provide a seamless workflow to FASP type digests. Consequently, the versatility of digest conditions, either FASP or on-bead digest - what we call BASP™, can offer many workflow and unique digest efficiency options. Collectively we continue to find new benefits for clinical discovery and targeted proteomics.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information on AlbuVoid™, go to: http://www.biotechsupportgroup.com/AlbuVoid-Albumin-Depletion-and-Low-Abundance-p/avk.htm

For more information on the BSG complete line of Albumin & IgG Removal products , visit: https://www.biotechsupportgroup.com/Articles.asp?ID=451

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com.

For Business Development, Contact:

Matt Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com